Abstract
Hans Bishop is profiled.
Hans Bishop began his role as CEO of Grail on June 7, replacing Jennifer Cook, MBA, who stepped down. Previously, he founded Juno Therapeutics, serving as president and CEO until the company was acquired by Celgene in 2018 and he joined its board of directors. Bishop was also a co-founder and the executive chairman of Sana Biotechnology, the chairman of Lyell ImmunoPharma, and a director of Agilent Technologies. He has held various other executive roles at Dendreon, Bayer, Chiron Corp., and European Biopharmaceuticals.
For more news on cancer research, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.
RSS Feeds